PL2978455T3 - Semifluorowęglowodorowy związek zawierający środek kontrastowy - Google Patents
Semifluorowęglowodorowy związek zawierający środek kontrastowyInfo
- Publication number
- PL2978455T3 PL2978455T3 PL14710891T PL14710891T PL2978455T3 PL 2978455 T3 PL2978455 T3 PL 2978455T3 PL 14710891 T PL14710891 T PL 14710891T PL 14710891 T PL14710891 T PL 14710891T PL 2978455 T3 PL2978455 T3 PL 2978455T3
- Authority
- PL
- Poland
- Prior art keywords
- semifluorocarbon
- compound containing
- contrast agent
- containing contrast
- agent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002872 contrast media Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- High Energy & Nuclear Physics (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Signal Processing (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmacology & Pharmacy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13160868.9A EP2783703A1 (en) | 2013-03-25 | 2013-03-25 | Semifluorocarbon compound containing contrast agent |
EP14710891.4A EP2978455B1 (en) | 2013-03-25 | 2014-03-18 | Semifluorocarbon compound containing contrast agent |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2978455T3 true PL2978455T3 (pl) | 2017-06-30 |
Family
ID=47913282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14710891T PL2978455T3 (pl) | 2013-03-25 | 2014-03-18 | Semifluorowęglowodorowy związek zawierający środek kontrastowy |
Country Status (17)
Country | Link |
---|---|
US (2) | US20160000941A1 (pl) |
EP (2) | EP2783703A1 (pl) |
JP (1) | JP6356780B2 (pl) |
KR (1) | KR102210774B1 (pl) |
CN (1) | CN105142681B (pl) |
BR (1) | BR112015017572A2 (pl) |
CA (1) | CA2893799C (pl) |
DK (1) | DK2978455T3 (pl) |
ES (1) | ES2616884T3 (pl) |
HU (1) | HUE030818T2 (pl) |
IL (1) | IL239203A (pl) |
MX (1) | MX362702B (pl) |
PL (1) | PL2978455T3 (pl) |
PT (1) | PT2978455T (pl) |
RU (1) | RU2672588C2 (pl) |
TW (1) | TWI652069B (pl) |
WO (1) | WO2014154531A1 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869345B (zh) | 2010-03-17 | 2015-02-11 | 诺瓦利克有限责任公司 | 用于治疗眼内压增高的药物组合物 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
EP2895158B1 (en) | 2012-09-12 | 2019-11-20 | Novaliq GmbH | Compositions comprising mixtures of semifluorinated alkanes |
EP3181119B1 (en) | 2012-09-12 | 2019-07-10 | Novaliq GmbH | Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca |
JP6503349B2 (ja) | 2013-07-23 | 2019-04-17 | ノバリック ゲーエムベーハー | 安定化された抗体組成物 |
DE202016008739U1 (de) | 2015-09-30 | 2019-04-29 | Novaliq Gmbh | Semifluorierte Verbindungen |
PT3355990T (pt) | 2015-09-30 | 2019-09-11 | Novaliq Gmbh | Compostos semifluorados e as suas composições |
EP3203256A1 (en) | 2016-02-02 | 2017-08-09 | B. Braun Melsungen AG | Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference |
KR102257916B1 (ko) | 2016-06-23 | 2021-05-28 | 노바리크 게엠베하 | 드롭 디스펜서를 포함하는 키트 |
CN109890374A (zh) | 2016-09-22 | 2019-06-14 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
WO2018193093A1 (en) | 2017-04-21 | 2018-10-25 | Novaliq Gmbh | Iodine compositions |
WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
CN110650734A (zh) | 2017-05-12 | 2020-01-03 | 诺瓦利克有限责任公司 | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 |
CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
AU2019345929B2 (en) | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
RU2723391C1 (ru) * | 2019-09-19 | 2020-06-11 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ определения тромбоза ушка левого предсердия по данным контрастной трансторакальной эхокардиографии |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0231091B1 (en) | 1986-01-24 | 1993-03-31 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
DE4405627A1 (de) * | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
IL163937A0 (en) | 2002-03-07 | 2005-12-18 | Univ Carnegie Mellon | Contrast agents for magnetic resonance imaging andmethods realted thereto |
EP1713513B1 (en) * | 2004-01-16 | 2014-06-04 | Carnegie Mellon University | Cellular labeling for nuclear magnetic resonance techniques |
RU2262920C1 (ru) * | 2004-09-28 | 2005-10-27 | Открытое Акционерное Общество "Фаберлик" | Водная эмульсия перфторсоединений для косметических и/или дерматологических препаратов и способ ее получения |
EP1885243A4 (en) | 2005-05-11 | 2014-05-21 | Univ Minnesota | METHODS AND DEVICE FOR REPRESENTING MAGNETIC INDUCTION |
DE102007015598A1 (de) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren |
CN102869345B (zh) * | 2010-03-17 | 2015-02-11 | 诺瓦利克有限责任公司 | 用于治疗眼内压增高的药物组合物 |
PT2661280T (pt) | 2011-01-04 | 2019-02-25 | Novaliq Gmbh | Emulsões o/a compreendendo alcanos semifluorados |
WO2013158265A1 (en) * | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
-
2013
- 2013-03-25 EP EP13160868.9A patent/EP2783703A1/en not_active Withdrawn
-
2014
- 2014-03-05 TW TW103107324A patent/TWI652069B/zh active
- 2014-03-18 JP JP2016504568A patent/JP6356780B2/ja active Active
- 2014-03-18 WO PCT/EP2014/055398 patent/WO2014154531A1/en active Application Filing
- 2014-03-18 HU HUE14710891A patent/HUE030818T2/en unknown
- 2014-03-18 CA CA2893799A patent/CA2893799C/en active Active
- 2014-03-18 US US14/759,444 patent/US20160000941A1/en not_active Abandoned
- 2014-03-18 DK DK14710891.4T patent/DK2978455T3/en active
- 2014-03-18 KR KR1020157026470A patent/KR102210774B1/ko active IP Right Grant
- 2014-03-18 CN CN201480016964.3A patent/CN105142681B/zh active Active
- 2014-03-18 RU RU2015130915A patent/RU2672588C2/ru active
- 2014-03-18 ES ES14710891.4T patent/ES2616884T3/es active Active
- 2014-03-18 MX MX2015013746A patent/MX362702B/es active IP Right Grant
- 2014-03-18 EP EP14710891.4A patent/EP2978455B1/en active Active
- 2014-03-18 PT PT147108914T patent/PT2978455T/pt unknown
- 2014-03-18 BR BR112015017572A patent/BR112015017572A2/pt not_active Application Discontinuation
- 2014-03-18 PL PL14710891T patent/PL2978455T3/pl unknown
-
2015
- 2015-06-04 IL IL239203A patent/IL239203A/en active IP Right Grant
-
2023
- 2023-05-02 US US18/310,588 patent/US20230355810A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2893799C (en) | 2021-03-09 |
US20160000941A1 (en) | 2016-01-07 |
IL239203A (en) | 2017-03-30 |
US20230355810A1 (en) | 2023-11-09 |
PT2978455T (pt) | 2017-02-24 |
MX362702B (es) | 2019-02-01 |
KR102210774B1 (ko) | 2021-02-02 |
EP2978455A1 (en) | 2016-02-03 |
JP2016515553A (ja) | 2016-05-30 |
MX2015013746A (es) | 2016-02-26 |
EP2978455B1 (en) | 2017-01-04 |
RU2672588C2 (ru) | 2018-11-16 |
HUE030818T2 (en) | 2017-06-28 |
BR112015017572A2 (pt) | 2017-07-11 |
WO2014154531A1 (en) | 2014-10-02 |
ES2616884T3 (es) | 2017-06-14 |
IL239203A0 (en) | 2015-07-30 |
CN105142681B (zh) | 2019-03-12 |
RU2015130915A3 (pl) | 2018-03-19 |
TWI652069B (zh) | 2019-03-01 |
CN105142681A (zh) | 2015-12-09 |
CA2893799A1 (en) | 2014-10-02 |
KR20150132836A (ko) | 2015-11-26 |
DK2978455T3 (en) | 2017-03-06 |
RU2015130915A (ru) | 2017-04-27 |
TW201524521A (zh) | 2015-07-01 |
JP6356780B2 (ja) | 2018-07-11 |
EP2783703A1 (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL249518A0 (en) | A compound that inhibits trk | |
IL239203A0 (en) | A semifluorocarbon compound containing a contrast agent | |
AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
GB201309085D0 (en) | Compounds | |
GB201302927D0 (en) | Compounds | |
GB201302368D0 (en) | Compound | |
GB201311951D0 (en) | Compounds | |
HK1219100A1 (zh) | 吡啶基吡唑並喹啉化合物 | |
AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
EP2947066A4 (en) | PHENOXYALKYLAMINVERBINDUNG | |
EP3010923A4 (en) | PYRROLOCHINAZOLINVERBINDUNGEN | |
EP2948457A4 (en) | COMPOUNDS | |
GB201307331D0 (en) | Compound | |
GB201408643D0 (en) | Compound | |
EP3037100A4 (en) | MEANS TO PREVENT MUSCLE ATROPHY | |
GB201306794D0 (en) | Compounds | |
GB201322438D0 (en) | Compound | |
GB201315772D0 (en) | Compound | |
GB201305634D0 (en) | Compound | |
GB201304250D0 (en) | Compound | |
GB201322028D0 (en) | Compounds | |
GB201301585D0 (en) | Compound | |
GB201318323D0 (en) | Compounds | |
GB201315253D0 (en) | Compounds | |
GB201303572D0 (en) | New Compound |